HRP20170246T1 - Režim doziranja za selektivni agonist s1p1-receptora - Google Patents
Režim doziranja za selektivni agonist s1p1-receptoraInfo
- Publication number
- HRP20170246T1 HRP20170246T1 HRP20170246TT HRP20170246T HRP20170246T1 HR P20170246 T1 HRP20170246 T1 HR P20170246T1 HR P20170246T T HRP20170246T T HR P20170246TT HR P20170246 T HRP20170246 T HR P20170246T HR P20170246 T1 HRP20170246 T1 HR P20170246T1
- Authority
- HR
- Croatia
- Prior art keywords
- selective
- receptor agonist
- dosing regimen
- regimen
- dosing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB2008050995 | 2008-03-17 | ||
EP09721703.8A EP2278960B2 (en) | 2008-03-17 | 2009-03-12 | Dosing regimen for a selective sip1 receptor agonist |
PCT/IB2009/051030 WO2009115954A1 (en) | 2008-03-17 | 2009-03-12 | Dosing regimen for a selective s1p1 receptor agonist |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20170246T1 true HRP20170246T1 (hr) | 2017-04-07 |
HRP20170246T4 HRP20170246T4 (hr) | 2020-02-07 |
Family
ID=40786618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170246TT HRP20170246T4 (hr) | 2008-03-17 | 2017-02-15 | Režim doziranja za selektivni agonist s1p1-receptora |
Country Status (27)
Country | Link |
---|---|
US (6) | US8785484B2 (hr) |
EP (1) | EP2278960B2 (hr) |
JP (2) | JP4846063B2 (hr) |
KR (3) | KR101718639B1 (hr) |
CN (2) | CN104800208A (hr) |
AR (1) | AR070842A1 (hr) |
AU (1) | AU2009227629B2 (hr) |
BR (1) | BRPI0909625B1 (hr) |
CA (1) | CA2716448A1 (hr) |
CY (1) | CY1118648T1 (hr) |
DK (1) | DK2278960T4 (hr) |
ES (1) | ES2617628T5 (hr) |
HR (1) | HRP20170246T4 (hr) |
HU (1) | HUE033168T2 (hr) |
IL (1) | IL208154A (hr) |
LT (1) | LT2278960T (hr) |
MA (1) | MA32233B1 (hr) |
MX (1) | MX2010009853A (hr) |
MY (1) | MY177360A (hr) |
NZ (1) | NZ588505A (hr) |
PL (1) | PL2278960T5 (hr) |
PT (1) | PT2278960T (hr) |
RU (1) | RU2519660C2 (hr) |
SI (1) | SI2278960T2 (hr) |
TW (1) | TWI434688B (hr) |
WO (1) | WO2009115954A1 (hr) |
ZA (1) | ZA201007367B (hr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100783835B1 (ko) | 2003-11-21 | 2007-12-10 | 액테리온 파마슈티칼 리미티드 | 면역억제제로서 5-(벤즈-(z)-일리덴-티아졸리딘-4-원유도체 |
USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
BRPI0718986A2 (pt) * | 2006-11-23 | 2014-02-11 | Actelion Pharmaceuticals Ltd | Processo para a preparação de um composto e composto resultante |
US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
EP2278960B2 (en) | 2008-03-17 | 2019-11-13 | Actelion Pharmaceuticals Ltd. | Dosing regimen for a selective sip1 receptor agonist |
GB0819182D0 (en) | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
EP3677260A1 (en) * | 2008-12-22 | 2020-07-08 | Novartis AG | Dosage regimen for a s1p receptor agonist |
JP5856980B2 (ja) | 2010-01-27 | 2016-02-10 | アリーナ ファーマシューティカルズ, インコーポレイテッド | (R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸およびその塩の調製のためのプロセス |
EP2566473B1 (en) * | 2010-05-06 | 2016-01-06 | Novartis AG | Dosage regimen of diaryl sulfide derivatives |
SG191286A1 (en) | 2011-01-07 | 2013-07-31 | Novartis Ag | Immunosuppressant formulations |
MX350891B (es) | 2012-08-17 | 2017-09-22 | Actelion Pharmaceuticals Ltd | Proceso para la preparacion de (2z,5z)-5-(3-cloro-4-((r)-2,3-dihid roxipropoxi) bencilideno)-2-(propilimino)-3-(o-tolil) tiazolidin-4-ona y el intermediario usado en dicho proceso. |
US20170165236A1 (en) | 2013-11-01 | 2017-06-15 | Celgene International Ii Sàrl | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
CN106999461A (zh) * | 2014-12-11 | 2017-08-01 | 埃科特莱茵药品有限公司 | 选择性s1p1受体激动剂的给药方案 |
MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
UA126268C2 (uk) | 2015-01-06 | 2022-09-14 | Арена Фармасьютікалз, Інк. | СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub> |
CA2973540A1 (en) | 2015-02-26 | 2016-09-01 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
CA3002551A1 (en) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders |
JP2020507610A (ja) | 2017-02-16 | 2020-03-12 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法 |
MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
JOP20190207A1 (ar) * | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
EP4051250A1 (en) | 2019-10-31 | 2022-09-07 | Idorsia Pharmaceuticals Ltd | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
CA3221343A1 (en) | 2021-10-11 | 2023-04-20 | Allitia DIBERNARDO | Methods of treating multiple sclerosis |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0627406T3 (da) | 1992-10-21 | 1999-07-12 | Taito Co | 2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler |
WO1997024112A1 (fr) | 1995-12-28 | 1997-07-10 | Yoshitomi Pharmaceutical Industries, Ltd. | Preparation a usage externe |
JPH11209277A (ja) * | 1998-01-19 | 1999-08-03 | Yoshitomi Pharmaceut Ind Ltd | 医薬組成物 |
US6476004B1 (en) | 1996-07-18 | 2002-11-05 | Mitsubishi Pharma Corporation | Pharmaceutical composition |
SI0990440T1 (sl) | 1997-02-27 | 2009-04-30 | Novartis Ag | Farmacevtski sestavek, ki obsega 2-amino-2-(2-(4-oktilfenil)etil)propan-1,3-diol, lecitin in saharid |
AU7687998A (en) | 1997-05-19 | 1998-12-11 | Sugen, Inc. | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders |
JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
AU2001278135A1 (en) * | 2000-08-03 | 2002-02-18 | Cytovia, Inc. | Method of identifying immunosuppressive agents |
MXPA03008999A (es) | 2001-04-02 | 2004-02-12 | Astrazeneca Ab | Composicion farmaceutica solida que comprende 4-ciano -trifluor-3 -(4-fluorfenilsulfonil) -2-hidroxi-2 -metilpropino -m-toluidida y pvp. |
CA2440831C (en) | 2001-04-02 | 2013-05-28 | Genentech, Inc. | Combination therapy using cd40 and cd20 ligands |
US6495025B2 (en) | 2001-04-20 | 2002-12-17 | Aerovironment, Inc. | Electrochemical oxygen generator and process |
AU2002316221A1 (en) * | 2001-05-16 | 2002-11-25 | Nicholas P. Plotnikoff | Methods for inducing sustained immune response |
ES2322442T3 (es) | 2001-06-08 | 2009-06-22 | Novartis Ag | Tratamiento o profilaxis del rechazo de injertos de celulas productoras de insulina. |
AU2002332289B2 (en) | 2001-09-27 | 2007-05-10 | Kyorin Pharmaceutical Co., Ltd. | Diaryl sulfide derivative, addition salt thereof, and immunosuppressant |
EP1431275B1 (en) | 2001-09-27 | 2010-04-07 | Kyorin Pharmaceutical Co., Ltd. | Diaryl ether derivative, addition salt thereof, and immunosuppressant |
CA2472680A1 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
ATE441654T1 (de) | 2002-01-18 | 2009-09-15 | Merck & Co Inc | Edg-rezeptoragonisten |
GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
CN1708293A (zh) | 2002-09-24 | 2005-12-14 | 诺瓦提斯公司 | 治疗脱髓鞘疾病的鞘氨醇-1-磷酸受体激动剂 |
HUE028247T2 (en) | 2003-04-08 | 2016-12-28 | Novartis Ag | A solid oral composition comprising S1P receptor agonist and sugar alcohol |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
KR100783835B1 (ko) | 2003-11-21 | 2007-12-10 | 액테리온 파마슈티칼 리미티드 | 면역억제제로서 5-(벤즈-(z)-일리덴-티아졸리딘-4-원유도체 |
USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
WO2005123677A1 (en) | 2004-06-16 | 2005-12-29 | Actelion Pharmaceuticals Ltd | 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents |
WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
WO2006041015A1 (ja) | 2004-10-12 | 2006-04-20 | Kyorin Pharmaceutical Co., Ltd. | アミノアルコール誘導体とその付加塩及び免疫抑制剤 |
US20060090658A1 (en) * | 2004-11-01 | 2006-05-04 | Michael Phillips | Tissue marking system |
MX2007006373A (es) | 2004-11-29 | 2007-06-20 | Novartis Ag | Regimen de dosificacion de un agonista del receptor s1p. |
WO2006100633A1 (en) | 2005-03-23 | 2006-09-28 | Actelion Pharmaceuticals Ltd | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-l-PHOSPHATE-1 RECEPTOR AGONISTS |
KR20080002850A (ko) | 2005-03-23 | 2008-01-04 | 액테리온 파마슈티칼 리미티드 | 신규한 티오펜 유도체 |
DK1863787T3 (da) | 2005-03-23 | 2011-08-01 | Actelion Pharmaceuticals Ltd | Hydrogeneret benzo[c]thiophenderivater som immunmodulatorer |
RU2008101805A (ru) | 2005-06-24 | 2009-07-27 | Актелион Фармасьютиклз Лтд (Ch) | Новые производные тиофена |
AR057894A1 (es) | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno |
TWI404706B (zh) | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
US8178562B2 (en) | 2006-01-24 | 2012-05-15 | Actelion Pharmaceuticals, Ltd. | Pyridine derivatives |
US7879821B2 (en) * | 2006-01-26 | 2011-02-01 | University Of Medicine And Dentistry Of New Jersey | Method for modulating inflammatory responses by altering plasma lipid levels |
TWI408139B (zh) | 2006-09-07 | 2013-09-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
ES2400533T3 (es) | 2006-09-07 | 2013-04-10 | Actelion Pharmaceuticals Ltd. | Derivados de piridin 4-ilo como agentes inmunomoduladores |
US8288554B2 (en) | 2006-09-08 | 2012-10-16 | Actelion Pharmaceuticals Ltd. | Pyridin-3-yl derivatives as immunomodulating agents |
EP2069318B1 (en) | 2006-09-21 | 2012-09-12 | Actelion Pharmaceuticals Ltd. | Phenyl derivatives and their use as immunomodulators |
BRPI0718986A2 (pt) | 2006-11-23 | 2014-02-11 | Actelion Pharmaceuticals Ltd | Processo para a preparação de um composto e composto resultante |
US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
PT2125797E (pt) | 2007-03-16 | 2014-03-11 | Actelion Pharmaceuticals Ltd | Derivados aminopiridina como agonistas do receptor s1p1/edg1 |
SI2195311T1 (sl) | 2007-08-17 | 2011-07-29 | Actelion Pharmaceuticals Ltd | Derivati piridina kot modulatorji receptorja s1p1/edg1 |
MY159358A (en) | 2007-10-12 | 2016-12-30 | Novartis Ag | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
EP2278960B2 (en) | 2008-03-17 | 2019-11-13 | Actelion Pharmaceuticals Ltd. | Dosing regimen for a selective sip1 receptor agonist |
RS54970B1 (sr) * | 2008-08-27 | 2016-11-30 | Arena Pharm Inc | Supstituisani triciklični derivati kiselina kao s1p1 receptor agonisti korisni pri lečenju autoimunih i upalnih poremećaja |
GB0819182D0 (en) | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
DK2379069T3 (en) | 2008-12-22 | 2015-06-08 | Novartis Ag | Dosage Plan for an S1P receptor agonist |
EP3677260A1 (en) | 2008-12-22 | 2020-07-08 | Novartis AG | Dosage regimen for a s1p receptor agonist |
JP5416600B2 (ja) | 2010-01-22 | 2014-02-12 | 株式会社日立ハイテクノロジーズ | 欠陥検査装置およびその方法 |
MX350891B (es) | 2012-08-17 | 2017-09-22 | Actelion Pharmaceuticals Ltd | Proceso para la preparacion de (2z,5z)-5-(3-cloro-4-((r)-2,3-dihid roxipropoxi) bencilideno)-2-(propilimino)-3-(o-tolil) tiazolidin-4-ona y el intermediario usado en dicho proceso. |
MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
CN106999461A (zh) | 2014-12-11 | 2017-08-01 | 埃科特莱茵药品有限公司 | 选择性s1p1受体激动剂的给药方案 |
-
2009
- 2009-03-12 EP EP09721703.8A patent/EP2278960B2/en active Active
- 2009-03-12 JP JP2011500324A patent/JP4846063B2/ja active Active
- 2009-03-12 PL PL09721703T patent/PL2278960T5/pl unknown
- 2009-03-12 AU AU2009227629A patent/AU2009227629B2/en active Active
- 2009-03-12 SI SI200931616T patent/SI2278960T2/sl unknown
- 2009-03-12 CA CA2716448A patent/CA2716448A1/en not_active Abandoned
- 2009-03-12 RU RU2010141579/15A patent/RU2519660C2/ru active
- 2009-03-12 ES ES09721703T patent/ES2617628T5/es active Active
- 2009-03-12 LT LTEP09721703.8T patent/LT2278960T/lt unknown
- 2009-03-12 PT PT97217038T patent/PT2278960T/pt unknown
- 2009-03-12 KR KR1020157002281A patent/KR101718639B1/ko active IP Right Grant
- 2009-03-12 KR KR1020147005406A patent/KR101653071B1/ko active IP Right Grant
- 2009-03-12 AR ARP090100886A patent/AR070842A1/es unknown
- 2009-03-12 KR KR1020107022801A patent/KR20100134032A/ko active IP Right Grant
- 2009-03-12 MX MX2010009853A patent/MX2010009853A/es active IP Right Grant
- 2009-03-12 WO PCT/IB2009/051030 patent/WO2009115954A1/en active Application Filing
- 2009-03-12 MY MYPI2010004328A patent/MY177360A/en unknown
- 2009-03-12 CN CN201510090161.9A patent/CN104800208A/zh active Pending
- 2009-03-12 CN CN2009801101149A patent/CN101980704A/zh active Pending
- 2009-03-12 US US12/922,777 patent/US8785484B2/en active Active
- 2009-03-12 BR BRPI0909625-6A patent/BRPI0909625B1/pt active IP Right Grant
- 2009-03-12 DK DK09721703.8T patent/DK2278960T4/da active
- 2009-03-12 HU HUE09721703A patent/HUE033168T2/en unknown
- 2009-03-12 NZ NZ588505A patent/NZ588505A/xx unknown
- 2009-03-16 TW TW098108497A patent/TWI434688B/zh active
-
2010
- 2010-09-15 IL IL208154A patent/IL208154A/en active IP Right Grant
- 2010-10-14 ZA ZA2010/07367A patent/ZA201007367B/en unknown
- 2010-10-15 MA MA33253A patent/MA32233B1/fr unknown
-
2011
- 2011-08-30 JP JP2011186874A patent/JP4938905B2/ja active Active
-
2014
- 2014-06-18 US US14/308,598 patent/US20140303217A1/en not_active Abandoned
- 2014-07-02 US US14/322,801 patent/US20140315964A1/en not_active Abandoned
- 2014-07-02 US US14/322,722 patent/US10660880B2/en active Active
-
2015
- 2015-06-05 US US14/732,013 patent/US10251867B2/en active Active
-
2017
- 2017-02-02 CY CY20171100154T patent/CY1118648T1/el unknown
- 2017-02-15 HR HRP20170246TT patent/HRP20170246T4/hr unknown
-
2021
- 2021-09-09 US US17/470,905 patent/US20210401811A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20170246T1 (hr) | Režim doziranja za selektivni agonist s1p1-receptora | |
IL278914A (en) | Dosing regimen for an S1P receptor agonist | |
LTPA2020513I1 (lt) | S1P receptoriaus agonisto dozavimas | |
EP2151236A4 (en) | G PROTEIN COUPLED RECEPTOR AGONIST | |
IL208919A0 (en) | Gpr119 receptor agonists | |
IL234296B (en) | dosage regimen | |
IL209151A0 (en) | A lid-container for independent mixing | |
EP2197448A4 (en) | dosing schedule | |
ZA201200641B (en) | Sphingosine-1-phosphate receptor agonists | |
IL207700A0 (en) | 3-aminoalkyl-1,4-diazepan-2-one melanocortin -5 receptor antagonists | |
IL207701A0 (en) | 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists | |
GB0804860D0 (en) | Dosing fill | |
IL212283A0 (en) | Thyroid receptor ligands |